Combining Varenicline and Guanfacine for Smoking Cessation

Last updated: July 22, 2025
Sponsor: Yale University
Overall Status: Completed

Phase

2

Condition

Smoking Cessation

Diabetes Prevention

Treatment

Varenicline

Guanfacine ER

Clinical Study ID

NCT04198116
2000026630
R01DA047986
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The novel design of this study combines a laboratory paradigm to evaluate stress-induced smoking behavior and smoking-related reinforcement, followed by a 12-week treatment phase to evaluate clinical outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18+

  2. Able to read and write English

  3. SMOKER: 10 or more cigarettes per day for at least the past year, Carbon Monoxide (CO) > 10 ppm at intake

  4. Able to take oral medications and willing to adhere to medication regimen

  5. Provide evidence of a stable living residence in the last 2 months prior torandomization, have reasonable transportation arrangements to the study site, haveno plans to move within the next 3 months, and have no unresolved legal problems

  6. Motivated to quit smoking (8 or greater on the Contemplation Ladder)

Exclusion

Exclusion Criteria:

  1. Subjects with any significant current medical conditions (neurological,cardiovascular [including hypertension or hypotension: sitting BP >160/100 or <90/60mmHg at baseline screening], endocrine, thyroid, renal, liver), seizures,delirium or hallucinations, or other unstable medical conditions

  2. Current Diagnostic and Statistical Manual of Mental Disorders (DSM-V) alcohol orsubstances use disorders, other than mild alcohol use disorder or tobacco usedisorder

  3. Subjects who have a positive test result at intake appointment on urine drug screensconducted for illicit drugs

  4. Past 30 day use of psychoactive drugs excluding anxiolytics and antidepressants (however, see #10; barbiturates, benzodiazepines are exclusionary)

  5. Women who are pregnant or nursing, or fail to use one of the following methods ofbirth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptivesponge, double barrier [diaphragm or condom plus spermicide], or IUD)

  6. Suicidal, homicidal or evidence of current (past 6-month) severe mental illness suchas schizophrenia or bipolar disorder

  7. meeting DSM-V criteria for current (past-6 month) attention deficit hyperactivitydisorder (ADHD)

  8. Individuals who are currently taking medications known to be effective for smokingcessation (e.g., FDA smoking cessation medications, nortriptyline, clonidine) or areregular users of e-cigarettes or other tobacco projects (pipe, cigar, smokelesstobacco) in the past 30 days

  9. Only one member per household can participate in the study

  10. Specific exclusions for administration of guanfacine not already specified: EKGevidence at baseline screening of any clinically significant conductionabnormalities or arrhythmias; known intolerance for guanfacine or any alpha blocker;history of fainting, syncopal attacks, heart failure or myocardial infarction, orimpaired liver (aspartate aminotransferase [AST], alanine aminotransferase [ALT] > 3x normal) or renal function (estimated creatinine clearance <60 cc/min); treatmentwith any antihypertensive drug or any alpha-blocker; use of any central nervoussystem (CNS) depressant (e.g., phenothiazines, barbiturates, benzodiazepines)

  11. Specific exclusions for the administration of varenicline not already specified:known intolerance to varenicline or taking H2blockers (e.g., Cimetidine),quinolones, or trimethoprim.

Study Design

Total Participants: 165
Treatment Group(s): 2
Primary Treatment: Varenicline
Phase: 2
Study Start date:
November 01, 2020
Estimated Completion Date:
April 30, 2025

Study Description

Using a double-blind, this Phase 2 study will randomize 140 smokers to a parallel group design (varenicline + guanfacine vs. varenicline alone). Following titration to steady state levels, the investigators will evaluate sex differences in medication effects on stress-induced smoking behavior and smoking-related reinforcement in the laboratory, and on abstinence outcomes during a subsequent 12-week treatment period.

Connect with a study center

  • Yale University

    New Haven, Connecticut 06519
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.